Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jun;77(12):2376–2380. doi: 10.1038/bjc.1998.395

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).

E Warner 1, R Goel 1, J Chang 1, W Chow 1, S Verma 1, J Dancey 1, E Franssen 1, H Dulude 1, M Girouard 1, J Correia 1, G Gallant 1
PMCID: PMC2150411  PMID: 9649162

Abstract

Cisplatin-based combination chemotherapy is frequently used to treat patients with carcinoma of unknown primary site (CUPS). Response rates in the literature range from 12% to 26% and median survival from 5 to 7 months. The goal of this study was to evaluate the combination of carboplatin and prolonged oral etoposide in patients with CUPS, with the hope of minimizing toxicity but improving efficacy and convenience. Treatment consisted of carboplatin, 300 mg m(-2) on day 1, and oral etoposide 50 mg on days 1-20, every 4 weeks for up to nine cycles. A total of 33 patients were treated and all were evaluable for toxicity. Non-haematological toxicity was mild to moderate, with the exception of one case of grade 4 stomatitis. Grade 4 leucopenia was observed in eight (24%) patients and sepsis in four (12%), with two and possibly three treatment-related deaths. For the 26 patients evaluable for response, the response rate was 23% with responses lasting a median of 11 months (range 7-13 months), with one patient still responding at 12 months. An additional nine patients (35%) had stable disease. Median survival for all patients was 5.6 months (range 2 weeks to 33 months). The combination of carboplatin with prolonged oral etoposide has moderate activity similar to that of other platinum-based regimens and is a well tolerated, convenient, outpatient regimen. Dosing according to estimated creatinine clearance to achieve a carboplatin AUC of 6.0 mg ml(-1) min might have decreased the incidence of severe myelotoxicity without compromising the regimen's efficacy.

Full text

PDF
2376

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese J. L., Abbruzzese M. C., Lenzi R., Hess K. R., Raber M. N. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995 Aug;13(8):2094–2103. doi: 10.1200/JCO.1995.13.8.2094. [DOI] [PubMed] [Google Scholar]
  2. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  3. Daugaard G. Unknown primary tumours. Cancer Treat Rev. 1994 Apr;20(2):119–147. doi: 10.1016/0305-7372(94)90024-8. [DOI] [PubMed] [Google Scholar]
  4. Eagan R. T., Therneau T. M., Rubin J., Long H. J., Schutt A. J. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol. 1987 Feb;10(1):82–85. doi: 10.1097/00000421-198702000-00018. [DOI] [PubMed] [Google Scholar]
  5. Einhorn L. H., Pennington K., McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol. 1990 Feb;17(1 Suppl 2):32–35. [PubMed] [Google Scholar]
  6. Evans W. K., Feld R., Osoba D., Shepherd F. A., Dill J., Deboer G. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer. 1984 Apr 1;53(7):1461–1466. doi: 10.1002/1097-0142(19840401)53:7<1461::aid-cncr2820530706>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  7. Gill I., Guaglianone P., Grunberg S. M., Scholz M., Muggia F. M. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. Anticancer Res. 1991 May-Jun;11(3):1231–1235. [PubMed] [Google Scholar]
  8. Greco F. A., Hainsworth J. D. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site. Semin Oncol. 1989 Aug;16(4 Suppl 6):116–122. [PubMed] [Google Scholar]
  9. Hainsworth J. D., Erland J. B., Kalman L. A., Schreeder M. T., Greco F. A. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol. 1997 Jun;15(6):2385–2393. doi: 10.1200/JCO.1997.15.6.2385. [DOI] [PubMed] [Google Scholar]
  10. Hainsworth J. D., Greco F. A. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993 Jul 22;329(4):257–263. doi: 10.1056/NEJM199307223290407. [DOI] [PubMed] [Google Scholar]
  11. Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F. A. Chronic daily administration of oral etoposide--a phase I trial. J Clin Oncol. 1989 Mar;7(3):396–401. doi: 10.1200/JCO.1989.7.3.396. [DOI] [PubMed] [Google Scholar]
  12. Hainsworth J. D., Johnson D. H., Greco F. A. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site. Cancer. 1991 Jan 1;67(1 Suppl):310–314. doi: 10.1002/1097-0142(19910101)67:1+<310::aid-cncr2820671317>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  13. Jelliffe R. W. Letter: Creatinine clearance: bedside estimate. Ann Intern Med. 1973 Oct;79(4):604–605. doi: 10.7326/0003-4819-79-4-604. [DOI] [PubMed] [Google Scholar]
  14. Levine M. N., Drummond M. F., Labelle R. J. Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin. CMAJ. 1985 Nov 15;133(10):977–987. [PMC free article] [PubMed] [Google Scholar]
  15. Miller J. C., Einhorn L. H. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol. 1990 Feb;17(1 Suppl 2):36–39. [PubMed] [Google Scholar]
  16. Sporn J. R., Greenberg B. R. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol. 1993 Jun;20(3):261–267. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES